The Questionnaires
Every clinical tool medicine uses to measure menopause symptoms — where they came from, what they cover, and what falls through the cracks.
When a woman walks into a doctor's office describing brain fog, rage, insomnia, and joint pain, the medical profession reaches for one of four standardised questionnaires. These tools define which symptoms "count" and put a number on the experience. They were built between 1953 and 1996. They've been translated, validated, and reviewed — but the symptoms they measure haven't meaningfully changed in over 20 years.
The Landscape
Four instruments make up the standard toolkit. Each was built in a different era, with different priorities, and each has significant blind spots.
| Tool | Year | Origin | Items | Scale | Admin | Last content change |
|---|---|---|---|---|---|---|
| Kupperman Index (KI) | 1953 | New York, USA | 11 | 0–3, weighted | Physician | 1959 |
| Greene Climacteric Scale (GCS) | 1976 | Glasgow, Scotland | 21 | 0–3 Likert | Self | 1998 |
| Menopause Rating Scale (MRS) | 1992 | Germany | 11 | 0–4 | Self | 2000 |
| MENQOL | 1996 | Toronto, Canada | 29 | 1–8 (bother) | Self | 2005 |
How They Compare
What each tool covers — and what falls through the cracks. ✓ = covered, ~ = partial, ✗ = missing.
| Symptom area | KI | GCS | MRS | MENQOL |
|---|---|---|---|---|
| Hot flushes / night sweats | ✓ | ✓ | ✓ | ✓ |
| Mood (anxiety, depression) | ~ | ✓ | ✓ | ✓ |
| Sleep disturbance | ✓ | ~ | ✓ | ✓ |
| Cognitive (brain fog, memory) | ✗ | ✗ | ✗ | ~ |
| Vaginal / urinary symptoms | ✗ | ✗ | ✓ | ~ |
| Sexual function | ✗ | 1 item | ✓ | ✓ |
| Weight changes | ✗ | ✗ | ✗ | ✓ |
| Joint / muscle pain | ✓ | ~ | ✓ | ✓ |
| Palpitations | ✓ | ✓ | ✓ | ✗ |
| Self-administered | Partial | ✓ | ✓ | ✓ |
| Validated for digital delivery | ✗ | ✗ | ✗ | ✗ |
| Designed for ongoing tracking | ✗ | ✗ | ✗ | ✗ |
What's Missing From All of Them
Cognitive symptoms — brain fog, difficulty concentrating, memory lapses, word-finding problems, and executive function disruption — are consistently reported as among the most distressing menopause symptoms. Research into the overlap between perimenopause cognitive symptoms and adult ADHD presentation is an active area of investigation. Yet these symptoms don't appear as distinct scored items in any of the four standard tools.
Urinary symptoms are missing from both the KI and the GCS — the two most widely used instruments. Even Greene acknowledged that the GCS "does not cover every possible symptom of menopause and in particular does not ask about vaginal and urinary changes."
Scoring resolution is low. A 4-point scale (used by both the KI and GCS) forces a woman to choose between "a little" and "quite a bit" — losing the difference between a 4/10 and a 7/10 day. Over time, this flattens data and makes it impossible to detect subtle trends.
Other Tools in the Field
Beyond the big four, several instruments target specific symptom domains or populations.
| Tool | Year | Items | Focus | Status |
|---|---|---|---|---|
| WHQ | 1992 | 37 | Broad midlife health | Validated, widely used |
| HFRDIS | — | 10 | Hot flash daily interference | Validated, narrow scope |
| CeMQ Daily Diary | — | Daily | Perimenopause tracking | Niche use |
| ZOE MenoScale | 2024 | 20 | Consumer symptom scoring | Not clinically validated |
| GAMS | 2025 | — | Proposed GCS replacement | New — not yet adopted |
37 items covering depression, anxiety, sleep, somatic symptoms, and more. Broader than menopause alone — covers midlife health generally. Reliable and sensitive to change, often used to assess HRT outcomes. Arguably as established as the big four but less frequently cited in menopause-specific research.
10 items measuring how vasomotor symptoms interfere with work, social activities, sleep, mood, concentration, and sexuality. Useful but narrow — only addresses hot flushes, not the full symptom picture.
Targets perimenopausal women specifically, including those with regular cycles who have hot flushes. Designed for daily tracking of cycles, symptoms, and treatments. One of the few tools explicitly designed for perimenopause rather than post-menopause.
20 questions producing a score out of 100. Consumer-facing rather than clinically validated. Part of a larger research programme into menopause and nutrition. Notable because it represents the first major consumer attempt to quantify menopause severity outside of clinical contexts entirely.
Proposed as a direct replacement for the GCS after a survey of 18,000+ women found the Greene Scale no longer performs well in modern populations. Uses weighted coefficients to improve diagnostic accuracy. The first serious attempt to replace a major clinical tool in 25 years.
Timeline
Seven decades of clinical measurement. Every creation, revision, validation, and critique.
| 1953 | KI | Blatt-Kupperman Menopausal Index published — NYU College of Medicine. 11 symptoms, physician-rated. |
| 1959 | KI | Modified version in JAMA — Establishes weighted scoring (hot flushes ×4). No new symptoms. |
| 1976 | GCS | Greene Climacteric Scale created — University of Glasgow. Factor analysis of 30 → 21 items. First self-report instrument. |
| 1984 | GCS | Methodological framework published. No item changes. |
| 1990 | GCS | Consensus report: "Toward a Consensual Measure." Groundwork for 1998 revision. |
| 1992 | WHQ | Women's Health Questionnaire published — King's College London. 37 items. |
| 1992–94 | MRS | MRS I developed in Germany — Physician-administered, 10 symptoms. |
| 1996 | MENQOL | MENQOL published — University of Toronto. 106 candidates → 29 via importance-scoring. |
| 1996–00 | MRS | MRS II — major revision — Converted to self-administered. 11th symptom added. |
| 1998 | KI | Alder publishes formal critique in Maturitas. Calls for retirement. |
| 1998 | GCS | GCS revised — Replaces 4 items, rewords 4. Splits psychological into anxiety/depression. |
| 2000 | MRS | Validation studies — Reliability confirmed. KI comparison (r = 0.91). SF-36 construct validity. |
| 2002–03 | MRS | International translations — English, French, Spanish, Swedish, Brazilian, Turkish, Indonesian. |
| 2004 | MRS | Comprehensive review — 9 countries, 4 continents. Treatment threshold ≥14. 9,000+ women. |
| 2005 | MENQOL | MENQOL-Intervention — 3 new physical items. Last content update to any major tool. |
| 2005–15 | Various | Population validations continue. GCS: Portuguese, Indian, Hong Kong. MENQOL: Arabic, Sinhala. No symptom changes. |
| 2015 | KI | Psychometric failure confirmed — "poor-fit indexes" via item response theory. |
| 2019 | KI | "The Kupperman Index Undressed" — Davis (Monash) questions validity in Maturitas. |
| 2021 | Review | Sourouni et al. notes "still several shortcomings" across all tools. |
| 2024 | ZOE | ZOE MenoScale launched — First major consumer-facing scoring tool. 20 questions, 0–100. |
| 2025 | GAMS | GAMS proposed — 18,000+ women. GCS found no longer representative. Weighted alternative. |
Deep Dives
Full profiles including methodology, domains, scoring, revision history, and documented limitations.
The oldest surviving tool in menopause medicine, developed by Herbert Kupperman and colleagues at NYU to evaluate estrogenic preparations. Created as a clinical scoring aid — the physician rated symptom severity alongside the patient, not a self-report measure.
Scores 11 symptoms on a 0–3 scale with weighting: hot flushes ×4, paresthesia ×2, insomnia ×2, everything else ×1. This weighting was never statistically justified.
| Symptoms | 11 — hot flushes, paresthesia, insomnia, nervousness, melancholia, vertigo, weakness, arthralgia/myalgia, headache, palpitations, formication |
| Scale | 0–3 (4 levels), weighted. Max ≈ 51 points |
| Administration | Physician-assisted |
| Domains | Not formally separated |
| Languages | Multiple (modified locally, no coordinated translations) |
| Access | Public domain |
| 1953 | Original publication in J Clin Endocrinol Metab. Mixed physician-rated and self-reported. 11 symptoms. |
| 1959 | Modified version in JAMA. Weighted scoring established. No new symptoms. |
| Various | Local modifications created in Asia and South America. No coordinated revision. |
| 1998 | Alder publishes formal critique in Maturitas. Calls for retirement. |
| 2015 | Psychometric failure confirmed. "Poor-fit indexes" via item response theory. |
| 2019 | "The Kupperman Index Undressed" — Davis (Monash) questions validity in Maturitas. |
No vaginal dryness. No libido. No urinary symptoms. No cognitive symptoms. No weight changes. No mood swings or rage. No demographic data from original sample was ever published.
Developed by Dr J.G. Greene using factor analysis of symptoms from women attending a menopause clinic. The most widely used menopause questionnaire globally, translated into 21+ languages.
| Symptoms | 21 |
| Scale | 0–3 Likert (4 levels). Max score 63 |
| Administration | Self-administered |
| Domains | 5: Anxiety (6), Depression (5), Somatic (7), Vasomotor (2), Sexual (1) |
| Languages | 21+ formal translations |
| Access | Open access |
| 1976 | Original publication in J Psychosom Res. 30 symptoms → 21 via factor analysis. |
| 1980 | Greene & Cooke life stress study. Early validation. |
| 1984 | Methodological framework published. No item changes. |
| 1990 | Consensus report: "Toward a Consensual Measure." Groundwork for 1998. |
| 1998 | Major revision. Reviews 7 studies. Replaces 4 items, rewords 4. Splits psychological into anxiety/depression. Adds sexual function probe. |
| 2000s–15 | Validated across Scottish, Dutch, Ecuadorian, Australian, Brazilian, Indian, Portuguese, Hong Kong Chinese populations. No symptom changes. |
| 2025 | GAMS proposed as replacement after 18,000+ woman study finds GCS no longer represents current populations. |
No vaginal or urinary symptoms — acknowledged by Greene himself. No cognitive symptoms. No weight changes. Only 1 sexual function item. No content changes since 1998.
Developed in Germany specifically to address Kupperman Index shortcomings. The most actively revised of the four tools, progressing from physician-administered to self-administered and internationally validated.
| Symptoms | 11 |
| Scale | 0–4 (5 levels). Max score 44 |
| Administration | Self-administered (MRS II) |
| Domains | 3: Somato-vegetative (4), Psychological (4), Urogenital (3) |
| Threshold | Total ≥14 indicates treatment need |
| Languages | 10+ formally assessed |
| Access | Open access |
| 1992–94 | MRS I developed. Physician-administered, 10 symptoms. |
| 1996–00 | MRS II — major revision. Self-administered. 11th symptom added. Standardised in German population. |
| 2000 | Validation published. 18-month reliability. KI comparison (r = 0.91). SF-36 construct validity. |
| 2002 | Reliability re-confirmed. English translation validated. |
| 2003 | International review: French, Spanish, Swedish, Brazilian, Turkish, Indonesian. |
| 2004 | Comprehensive review. 9 countries, 4 continents. Threshold ≥14 established. HRT validation with 9,000+ women. |
| 2013 | Chinese correlation study. KI correlation 0.74 but only "fair" severity agreement. |
No cognitive symptoms. No weight changes. No detailed musculoskeletal breakdown. Only 11 symptoms total. No changes since MRS II (2000).
The most comprehensive standard tool. Developed using a patient-centred methodology — 106 potential symptoms reduced to 29 via importance-scoring by actual menopausal women. Uses a distinctive two-part response: symptom present (yes/no) + bother level (0–6), creating an effective 8-level scale.
| Symptoms | 29 (original) / 32 (Intervention version, 2005) |
| Scale | 1–8 (present/absent + bother). Max score 232 |
| Administration | Self-administered |
| Domains | 4: Vasomotor (3), Psychosocial (7), Physical (16), Sexual (3) |
| Languages | 12+ (formal linguistic/cultural adaptation) |
| Access | Copyright-restricted (Mapi Research Trust) |
| 1996 | Original publication in Maturitas. 106 → 29 symptoms via importance-scoring with 88 women. |
| Late 1990s | Translations begin. Finnish, Italian, Polish, Danish, Norwegian, Dutch, French, Spanish, Portuguese. |
| 2005 | MENQOL-Intervention. 3 new physical items (→ 32). Scoring guidance and missing-data rules formalised. |
| 2012 | Psychometric properties confirmed in breast cancer survivors. |
| Various | Additional translations: Sinhala, Odia, Arabic. Cantonese version found not appropriate for mainland China. |
Copyright-restricted. Built exclusively with postmenopausal women. 29-item length less practical for frequent tracking. No core content changes since 2005.
Related Dashboards
Understand the Experience
Testing & Tracking
The Bigger Picture
Sources
- Kupperman, H.S. et al. (1953). Comparative clinical evaluation of estrogenic preparations. J Clin Endocrinol Metab, 13(6), 688–703.
- Kupperman, H.S. et al. (1959). Contemporary therapy of the menopausal syndrome. JAMA, 171, 1627–1637.
- Alder, E. (1998). The Blatt-Kupperman menopausal index: a critique. Maturitas, 29(1), 19–24.
- Greene, J.G. (1976). A factor analytic study of climacteric symptoms. J Psychosom Res, 20, 425–430.
- Greene, J.G. (1984). The Social and Psychological Origins of the Climacteric Syndrome. Gower: Aldershot.
- Greene, J.G. (1998). Constructing a standard climacteric scale. Maturitas, 29(1), 25–31.
- Hauser, G.A. et al. (1994). Evaluation der klinischen Beschwerden (MRS). Zentralbl Gynakol, 116, 16–23.
- Potthoff, P. et al. (2000). MRS: Methodische Standardisierung. Zentralbl Gynakol, 122, 280–286.
- Schneider, H.P.G. et al. (2000). MRS: Reliability of scores. Climacteric, 3, 59–64.
- Schneider, H.P.G. et al. (2000). MRS: Comparison with KI and SF-36. Climacteric, 3, 50–58.
- Heinemann, K. et al. (2002). Reliabilität der MRS. Zentralbl Gynakol, 124, 161–163.
- Heinemann, L.A.J. et al. (2003). International versions of the MRS. Health Qual Life Outcomes, 1, 28.
- Heinemann, K. et al. (2004). MRS: A methodological review. Health Qual Life Outcomes, 2, 45.
- Heinemann, L.A. et al. (2004). MRS as outcome measure for HRT. Health Qual Life Outcomes, 2, 67.
- Hilditch, J.R. et al. (1996). A menopause-specific quality of life questionnaire. Maturitas, 24(3), 161–175.
- Lewis, J.E. et al. (2005). Further psychometric development of MENQOL. Maturitas, 50(3), 209–221.
- Cogo-Moreira, H. et al. (2015). Poor-fit indexes of Kupperman index. Menopause, 22, 444–447.
- Davis, S.R. (2019). The Kupperman Index undressed. Maturitas.
- Tao, M. et al. (2013). Correlation between KI and MRS. Patient Prefer Adherence, 7, 223–229.
- Sourouni, M. et al. (2021). Assessment of the climacteric syndrome. Arch Gynecol Obstet, 304(4), 855–862.
- GAMS scale validity and performance (2025). Maturitas.
- Hemachandra, C. et al. (2024). Systematic review of menopause guidelines. BMJ Sex Reprod Health, 50(2), 122–138.